Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) dropped 1.3% during trading on Friday . The stock traded as low as $387.63 and last traded at $388.19, with a volume of 389,422 shares trading hands. The stock had previously closed at $393.40.

Several equities research analysts have issued reports on REGN shares. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. Canaccord Genuity restated a “hold” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, June 17th. Vetr upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $473.05 price objective on the stock in a report on Monday, August 8th. Citigroup Inc. restated a “buy” rating and set a $470.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 23rd. Finally, Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a report on Wednesday, June 29th. They set an “outperform” rating and a $400.00 price objective on the stock. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $470.73.

The company has a 50 day moving average price of $407.35 and a 200-day moving average price of $389.38. The stock has a market cap of $40.66 billion and a P/E ratio of 60.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.65 by $0.17. The firm earned $1.21 billion during the quarter, compared to analyst estimates of $1.24 billion. The company’s revenue was up 21.4% on a year-over-year basis. During the same period last year, the company earned $2.89 EPS. On average, analysts forecast that Regeneron Pharmaceuticals Inc. will post $10.93 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the transaction, the director now owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Sanofi purchased 64,731 shares of the business’s stock in a transaction on Tuesday, June 14th. The stock was purchased at an average cost of $363.86 per share, with a total value of $23,553,021.66. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Regeneron Pharmaceuticals stock. Schwab Charles Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 16.8% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 218,216 shares of the biopharmaceutical company’s stock after buying an additional 31,441 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.21% of Regeneron Pharmaceuticals worth $118,463,000 at the end of the most recent quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.